Sinopia Biosciences Selects Lead Clinical Candidate, Secures Funding to Advance into the Clinic for Parkinson’s Disease

SAN DIEGO–(BUSINESS WIRE)–Sinopia Biosciences, Inc., a biotechnology company advancing novel therapeutics identified using its proprietary computational drug discovery platform, announced today that it has selected SB-0110 after extensive preclinical studies as its lead clinical candidate for Parkinson’s disease and levodopa-induced dyskinesia. By successfully meeting this milestone, Sinopia has triggered Phase II funding of its Fast Track Small Business Innovation Research (SBIR) grant for a cumulative funding of $3.3M awarded by the National Institute of Neurological Disorders and Stroke (NINDS), a part of the National Institutes of Health (NIH). Further, Sinopia has been selected to receive $2.0M in funding from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) to advance SB-0110 into Phase 1 clinical trials.

“We are excited to select our lead clinical candidate, SB-0110, and to secure funding from two premier research institutions that are committed to advancing novel therapeutics for Parkinson’s disease,” said Iman Famili, Ph.D., President and Chief Executive Officer of Sinopia Biosciences. “Parkinson’s disease remains a disease area of high unmet clinical need, as current treatments are not optimal and can lead to long-term liabilities with chronic use.”

SB-0110 is a novel, proprietary small molecule with a unique mechanism of action that was identified using Sinopia’s LEADS™ platform, a next-generation drug discovery engine driven by machine learning and multi-omics network analysis to discover and prioritize targets and compounds. SB-0110 was selected from a series of compounds developed by Sinopia. In multiple preclinical rodent and non-human primate studies, Sinopia’s compounds have demonstrated a unique and potentially transformative pharmacology for treating both the symptoms of Parkinson’s disease and also the complications of levodopa, (i.e., levodopa-induced dyskinesia). Further, Sinopia’s compounds have demonstrated potential for cognitive enhancing effects in non-human primate models of Parkinson’s disease, an area of high unmet need with no approved treatments.

“SB-0110 is highly differentiated from current treatments and those that are currently in clinical development. We are excited to begin IND-enabling studies and are committed to advance the program to clinical studies,” said Aarash Bordbar, Ph.D., Co-founder and Chief Technology Officer of Sinopia Biosciences.

Research reported in this publication was supported by the National Institute of Neurological Disorders And Stroke of the National Institutes of Health under Award Number 4R44NS124398-02. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

About Sinopia Biosciences

Sinopia Biosciences, Inc. is a biotechnology company advancing novel therapeutics identified using its proprietary computational drug discovery platform. Sinopia’s discovery platform combines high-throughput omics data, machine learning, and network biology. Sinopia is headquartered at JLABS San Diego. For more information, please visit www.sinopiabio.com/.

Contacts

Company Contact:

Iman Famili, Ph.D.

[email protected]